Prostate Cancer

According to the authors, the optimal duration of treatment could be tied to individual patient factors such as cancer risk.

Rahul Aggarwal, MD, shares key takeaways from the PRESTO trial as well as remaining questions in the field.

Stacy Loeb, MD, MSc, PhD (Hon), debunks common misconceptions about prostate cancer and offers suggestions as to how urologists can help push back against misinformation.

The clearance supports new ultrasound imaging and workflow enhancements to the Focal One i, which was launched earlier this year.

The phase 3 AMPLITUDE trial evaluated the safety and efficacy of adding niraparib to abiraterone acetate plus prednisone in patients with mHSPC.

The ExactVu micro-ultrasound platform demonstrated noninferior detection of clinically significant prostate cancer vs MRI.

A major portion of the discussion focused on selecting among ARPIs for use with ADT in the mCSPC setting.

Jason M. Hafron, MD, CMO, touches on the growing shift toward biomarker-driven therapy in advanced prostate cancer.

Jason M. Hafron, MD, recaps noteworthy prostate cancer research from ESMO 2025.

Stacy Loeb, MD, discussed key takeaways from the European Randomized Study of Screening for Prostate Cancer.

Stacy Loeb, MD, shares key takeaways from her LUGPA 2025 session, “Current state of prostate cancer screening.”

Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation.

Henderson emphasized the evolving role of advanced biomarkers in refining prostate cancer risk assessment beyond traditional PSA testing

The phase 1b trial is assessing ORIC-944 both in combination with darolutamide and apalutamide.

Collins stresses the oncological importance of local control, as local recurrences can lead to a "second wave of metastatic disease" that can ultimately cause death.

Alice Bernard-Tessier, MD, highlights preliminary results from a phase 1 trial of gedatolisib plus darolutamide in mCRPC.

"I think MRI has really been perhaps the most transformative development in the realm of prostate cancer screening since I came into the field," says Stacy Loeb, MD, MSc, PhD (Hon.

"It's been a very exciting time for the radioligand space," says J. Travis Mendel, MD.

The rectal spacer showed sustained preservation of bowel, urinary, and sexual quality of life through 4 years of follow-up.

Panelists emphasized that the decision between doublet and triplet therapy must be individualized.

A major focus of the discussion was the growing role of darolutamide (Nubeqa) in the management of mCSPC.

212Pb-ADVC001 is a PSMA-targeted alpha-emitting radioligand therapy.

Bertrand Tombal, MD, PhD, shares insights from the real-world REASSURE trial.

The phase 3 PSMAddition trial assessed the combination of 177Lu-PSMA-617 plus ADT/ARPI in an earlier stage of metastatic prostate cancer.

Taylor Goodstein, MD, and Pretesh Patel, MD, explore how image guidance and adaptive radiation planning have revolutionized precision, even allowing real-time treatment plan adjustments.